Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

BACKGROUND: Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identified yet. Specific VEGF polymorphisms may affect gene transcription and therefore indirectly influence the efficacy of bevacizumab. METHODS: Genomic DNA of 111 consecutive metastatic colorectal cancer p...

Descripción completa

Detalles Bibliográficos
Autores principales: Loupakis, Fotios, Ruzzo, Annamaria, Salvatore, Lisa, Cremolini, Chiara, Masi, Gianluca, Frumento, Paolo, Schirripa, Marta, Catalano, Vincenzo, Galluccio, Nadia, Canestrari, Emanuele, Vincenzi, Bruno, Santini, Daniele, Bencardino, Katia, Ricci, Vincenzo, Manzoni, Mariangela, Danova, Marco, Tonini, Giuseppe, Magnani, Mauro, Falcone, Alfredo, Graziano, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125285/
https://www.ncbi.nlm.nih.gov/pubmed/21669012
http://dx.doi.org/10.1186/1471-2407-11-247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125285/
https://www.ncbi.nlm.nih.gov/pubmed/21669012
http://dx.doi.org/10.1186/1471-2407-11-247

Ejemplares similares